What is Gyre Therapeutics, Inc.'s market cap?

Gyre Therapeutics, Inc. (GYRE) has a market capitalization of $683.4M and trades on NASDAQ.

What is Gyre Therapeutics, Inc.'s revenue and profitability?

Gyre Therapeutics, Inc. generated $117.0M in trailing twelve-month revenue with a net loss of $1.9M, representing a net margin of 6.3%. Gross margin stands at 95.1%, with free cash flow of $3.1M. These figures are based on the Q1 2026 filing.

Who are Gyre Therapeutics, Inc.'s competitors?

Gyre Therapeutics, Inc.'s key competitors include Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Eli Lilly and Company, and others. These companies compete in similar markets and product categories.

Who does Gyre Therapeutics, Inc. partner with?

Gyre Therapeutics, Inc.'s notable partners include GNI Group, Ltd., Jiangsu Wangao Pharmaceuticals Co., Ltd., Nanjing Healthnice Pharmaceutical Technology Co., Ltd., and others.

What subsidiaries does Gyre Therapeutics, Inc. have?

Gyre Therapeutics, Inc.'s subsidiaries include Beijing Continent Pharmaceuticals Co., Ltd., Beijing Continent Biomedical Technology Co., Ltd., Helix Merger Sub Corp..

Where is Gyre Therapeutics, Inc. headquartered?

Gyre Therapeutics, Inc. is headquartered in United States of America and employs approximately 391 people. It has been publicly traded since 2023.

Gyre Therapeutics, Inc.

GYRE

Gyre Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule therapies for organ fibrosis and inflammatory diseases.

Market cap

$683.43M+3.7%

Revenue$117.0M+16.3%

Net income-$1.9M-116%

Free cash flow$3.1M+142%

EPS (diluted)-$0.07-240%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$22.5MMiss by $9.1M EPS-$0.05Beat by $0.01

Read the full report

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$26.5M

EPS estimate-$0.08

Financials

Q1 2026

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

EPS (diluted)-$0.10—

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation & ratios

Valuation

See full

Market cap$683.43M+3.7%

Enterprise value$646.75M-3.9%

P/S5.8×-1.1×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

FCF margin2.6%—

Returns & leverage

See full

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Segments

By segment

See full

Gyre Pharmaceuticals$22.5M+2.1%

All Other Segments-—

Gyre-—

By product

See full

Contiva$849.0+204%

Etorel$672.0—

Other Product$31.0-57.5%

Competitors

By market cap

Eli Lilly$1.07T+47.2%

BridgeBio Pharma$16.5B+87.7%

Madrigal Pharmaceuticals, Inc.$12.7B+94.6%

LQD

Liquidia Corporation$7.5B+343%

Viking Therapeutics$4.0B+8.4%

Theravance Biopharma$873.8M+58.0%

Gyre Therapeutics, Inc.$683.4M-3.5%

Fulcrum Therapeutics, Inc.$248.5M-41.0%

By revenue growth

LQD

Liquidia Corporation+1,937%

BridgeBio Pharma+355%

Madrigal Pharmaceuticals, Inc.+257%

Theravance Biopharma+68.2%

Eli Lilly+47.4%

Gyre Therapeutics, Inc.+16.3%

By net margin

Theravance Biopharma104.34%+194pp

Eli Lilly34.99%+12.3pp

Gyre Therapeutics, Inc.6.29%-13.8pp

Madrigal Pharmaceuticals, Inc.-27.32%+96.1pp

BridgeBio Pharma-125.85%+405pp

LQD

Liquidia Corporation-176.24%+896pp

Profile

Gyre Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule therapies for organ fibrosis and inflammatory diseases. The company leverages a revenue-generating commercial foundation in China to fund and de-risk its innovative pipeline, including late-stage candidates for liver and pulmonary conditions. Its core value proposition centers on addressing significant unmet medical needs in chronic fibrotic progression across multiple organ systems.

Competitive position

Gyre is a leading participant in the Chinese pulmonary fibrosis market with the first-in-class approval of ETUARY and is advancing the most clinically advanced liver fibrosis candidate in the PRC.

GeographiesChina, United States

Customer segmentsHospitals, Specialty Care Providers, Patients

Business modelResearch and Development, Manufacturing, Direct Sales, Licensing

SuppliersContract Development and Manufacturing Organizations (CDMOs), Raw material and API suppliers, Clinical Research Organizations (CROs)

CustomersPharmaceutical distributors, Public hospitals, Medical institutions, Retail pharmacies

CountryUnited States of America

Listed2023

Employees391.0

CEOYing Luo

SectorHealthcare

IndustryBiotechnology

Websitegyretx.com

FilingsSEC EDGAR

Ask your AI about Gyre Therapeutics, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s market cap?: Gyre Therapeutics, Inc. (GYRE) has a market capitalization of $683.4M and trades on NASDAQ.
What is Gyre Therapeutics, Inc.'s revenue and profitability?: Gyre Therapeutics, Inc. generated $117.0M in trailing twelve-month revenue with a net loss of $1.9M, representing a net margin of 6.3%. Gross margin stands at 95.1%, with free cash flow of $3.1M. These figures are based on the Q1 2026 filing.
Who are Gyre Therapeutics, Inc.'s competitors?: Gyre Therapeutics, Inc.'s key competitors include Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
Who does Gyre Therapeutics, Inc. partner with?: Gyre Therapeutics, Inc.'s notable partners include GNI Group, Ltd., Jiangsu Wangao Pharmaceuticals Co., Ltd., Nanjing Healthnice Pharmaceutical Technology Co., Ltd., and others.
What subsidiaries does Gyre Therapeutics, Inc. have?: Gyre Therapeutics, Inc.'s subsidiaries include Beijing Continent Pharmaceuticals Co., Ltd., Beijing Continent Biomedical Technology Co., Ltd., Helix Merger Sub Corp..
Where is Gyre Therapeutics, Inc. headquartered?: Gyre Therapeutics, Inc. is headquartered in United States of America and employs approximately 391 people. It has been publicly traded since 2023.